Eltrombopag

• 产品号: S2229
• CAS号: 496775-61-2
• 分子式: C25H22N4O4
• 分子量: 442.46658
• 保 存: -20°C

产品别名

• 标题: Eltrombopag
• IUPAC标准名: 3-(3-{2-[(4E)-1-(3,4-dimethylphenyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-4-ylidene]hydrazin-1-yl}-2-hydroxyphenyl)benzoic acid
• IUPAC传统名: eltrombopag
• 别名: Promacta; Revolade; SB-497115-GR

产品登记号

• CAS号: 496775-61-2

产品性质

• 作用靶点: TpoR
• 成盐信息: Free Base
• 保存条件: -20°C

产品详细信息

详细说明 (English)

Research Area: Cancer
Biological Activity:
Eltrombopag (SB-497115-GR, Promacta, Revolade) is a small molecule agonist of the c-mpl (TpoR) receptor with an IC50 of 0.69 μM for the inhibition of hERG K+ channel tail current. In preclinical studies, the compound was shown to interact selectively with the thrombopoeitin receptor, leading to activation of the JAK-STAT signaling pathway and increased proliferation and differentiation of megakaryocytes. Animal studies confirmed that administration could increase platelet counts.In addition, eltrombopag (SB-497115-GR, Promacta, Revolade) decreased proliferation of all cancer cell lines. [1][2]

参考文献

• Erickson-Miller CL et al. Leuk Res. 2010 Sep;34(9):1224-31.